GlobeNewsWire
23 Jun 2026, 05:15 UTC · 3h ago
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
23 Jun 2026, 05:15 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Japan's Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization for Wayrilz (rilzabrutinib) to treat persistent or chronic immune thrombocytopenia (ITP). — Regulatory approval in a major market like Japan opens a new revenue stream and validates the drug's efficacy.
+0.40Wayrilz is now approved for the treatment of ITP in the US, EU, UAE, UK, and Japan. — Broad global regulatory acceptance reduces clinical risk and increases the total addressable market for the product.
+0.30Sanofi is investigating Wayrilz for additional indications, including IgG4-related disease, warm autoimmune hemolytic anemia, and sickle cell disease. — Potential pipeline expansion into other rare diseases provides long-term growth optionality beyond ITP.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Sanofi received marketing and manufacturing authorization for Wayrilz in Japan to treat immune thrombocytopenia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
14h ago
